MoonLake Immunotherapeutics (MLTX) Capital Expenditures (2021 - 2025)

MoonLake Immunotherapeutics' Capital Expenditures history runs 5 years deep, the most recent figure standing at $35000.0 for Q1 2025.

• In Q1 2025, Capital Expenditures fell 83.49% year-over-year to $35000.0; the TTM figure through Dec 2025 stood at $35000.0 (down 93.27% YoY), while the FY2025 annual figure was $35000.0, down 93.27% from the prior year.
• Capital Expenditures was $35000.0 for Q1 2025 at MoonLake Immunotherapeutics, down from $176000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $284000.0 in Q4 2023 to a low of -$2.0 in Q2 2022.
• Historically, Capital Expenditures has averaged $91736.8 across 5 years, with a median of $42855.0 in 2021.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures sank 100.0% in 2022, then jumped 28399900.0% in 2023.
• A 5-year view of Capital Expenditures shows it stood at $50710.0 in 2021, then tumbled by 100.0% to $1.0 in 2022, then surged by 28399900.0% to $284000.0 in 2023, then plunged by 38.03% to $176000.0 in 2024, then sank by 80.11% to $35000.0 in 2025.
• The last three Capital Expenditures figures came in at $35000.0 (Q1 2025), $176000.0 (Q4 2024), and $132000.0 (Q3 2024), per Business Quant data.